The epithelium of the gastrointestinal tract is exposed to a variety of trypsin-like proteases that can activate PAR2
This article examines the relationship between GLP-1 medications and stool colour, providing evidence-based guidance on managing digestive symptoms and recognising warning signs requiring clinical assessment
Before using Wegovy , tell your healthcare provider if you have any other medical conditions, including if you: have or have had problems with your pancreas or kidneys have type 2 diabetes and a history of diabetic retinopathy are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation) are pregnant or plan to become pregnant
Your health care team may prescribe a GLP-1 drug as part of your treatment plan to keep your blood sugar in a safe range
Gastrointestinal symptomsparticularly nausea, vomiting, diarrhoea, and constipationare the most frequently reported adverse effects of GLP-1 receptor agonists, occurring in 2050% of patients depending on the specific agent and dose according to clinical trials and SmPC data
Inflammation promotes insulin resistance and fatty liver